RxDoctor Payments Data

Jimmy Hawkins, MD

Internal Medicine · Knoxville, TNNPI 1245274679

Payments from drug & device makers

$1,365in general payments, 2019–2025

Across 97 payments — averaging $14.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$469
  • Amgen$341
  • GSK$220
  • Pfizer$80
  • Biohaven Pharmaceuticals, Inc.$72
  • Dexcom, Inc.$45
  • plus $137 from 8 others

What the payments were for

  • Food & beverage$1,365100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)38$469
Amgen(2 entities)23$341
GSK15$220
Pfizer5$80
Biohaven Pharmaceuticals, Inc.5$72
Dexcom, Inc.2$45
Abbott2$36
Philips North America LLC1$19
Esperion Therapeutics, Inc.1$17
Antares Pharma, Inc.1$17
Novo Nordisk1$14
Boston Scientific1$13
Eisai Inc.1$13
Bardy Diagnostics, Inc.1$8

How this compares

$1,365 in reported general payments places this provider in the 70th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$183,567
Medicare patients
247
Services billed
7,575

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide88$91,507
OzempicSemaglutide68$88,074
EliquisApixaban90$80,742
JardianceEmpagliflozin16$21,107
TrulicityDulaglutide11$17,559
FarxigaDapagliflozin Propanediol11$16,236
JanuviaSitagliptin Phosphate18$12,830
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$7,907
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$4,967
Atorvastatin Calcium406$3,611
Levothyroxine Sodium416$3,541
Novolog FlexpenInsulin Aspart13$3,433
Testosterone12$2,405
Metoprolol Succinate134$2,381
Omeprazole196$1,804

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$14$88,07468 claims
PfizerEliquis$80$80,74290 claims
AbbVieSynthroid$469$1,07437 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →